The influence of mesenchymal stem cells on the severity of hypoxic-ischemic brain damage in neonatal rats via serum cytokines
View abstract on PubMed
Summary
This summary is machine-generated.Serum levels of IL-6, IL-18, and TNF-α correlate with neonatal hypoxic-ischemic brain damage (HIBD) severity in rats. Mesenchymal stem cell treatment reduces these cytokines, alleviating inflammation and repairing brain injury.
Area Of Science
- Neuroscience
- Regenerative Medicine
- Biochemistry
Background
- Neonatal hypoxic-ischemic brain damage (HIBD) is a severe neurological disorder with significant long-term consequences.
- Early diagnosis and intervention are critical for improving HIBD prognosis.
Purpose Of The Study
- Investigate the correlation between serum cytokine levels (IL-6, IL-18, TNF-α) and HIBD severity in neonatal rats.
- Evaluate the therapeutic effects of mesenchymal stem cells (MSCs) on cytokine levels and HIBD repair.
Main Methods
- Established a HIBD model in 7-day-old Sprague-Dawley rats using the Rice-Vannucci method.
- Administered MSCs to HIBD rats and assessed Longa scores, serum cytokine levels, and brain tissue damage via HE staining.
- Analyzed correlations between serum cytokines, HIBD severity, and MSC treatment efficacy.
Main Results
- Elevated serum IL-6, IL-18, and TNF-α levels were significantly correlated with HIBD severity in rats.
- MSC treatment significantly reduced serum cytokine levels and improved brain tissue damage in HIBD rats.
- Longa scores and inflammatory markers decreased significantly post-MSC intervention.
Conclusions
- Serum IL-6, IL-18, and TNF-α levels serve as reliable indicators of HIBD severity and brain injury.
- Mesenchymal stem cell therapy effectively mitigates inflammatory responses, improves symptoms, and promotes neural repair in HIBD.

